Assessment of Clinical Pharmacokinetic Drug-Drug Interaction of Antimalarial Drugs α/β-Arteether and Sulfadoxine-Pyrimethamine

Abstract

Antimalarial drug combination therapy is now being widely used for the treatment of uncomplicated malaria. The objective of the present study was to investigate the effects of coadministration of intramuscular α/β-arteether (α/β-AE) and oral sulfadoxine-pyrimethamine (SP) on the pharmacokinetic properties of each drug as a drug-drug interaction study to support the development of a fixed-dose combination therapy. A single-dose, open-label, crossover clinical trial was conducted in healthy adult Indian male volunteers (18 to 45 years, = 13) who received a single dose of AE or SP or a combination dose of AE and SP. Blood samples were collected up to 21 days postadministration, and concentrations of α-AE, β-AE, sulfadoxine, and pyrimethamine were determined by using a validated liquid chromatography-tandem mass spectrometry method. Pharmacokinetic parameters were calculated and statistically analyzed to calculate the geometric mean ratio and confidence interval. Following single-dose coadministration of intramuscular AE and oral SP, the pharmacokinetic properties of α/β-AE were not significantly affected, and α/β-AE had no significant effect on the pharmacokinetic properties of SP in these selected groups of healthy volunteers. However, more investigations are needed to explore this further. (This study has been registered in the clinical trial registry of India under approval no. CTRI/2011/11/002155.).

Molecular Docking and Dynamics Simulation Revealed Ivermectin as Potential Drug against Schistosoma-Associated Bladder Cancer Targeting Protein Signaling: Computational Drug Repositioning Approach

“…As first-line antimalarial medicines, arteether is safe, low-toxic and well tolerable. Furthermore, outcomes from a limited number of clinical trials provide encouraging evidence for their excellent antitumor activities [ 54 , 55 ]. However, some problems such as poor solubility, toxicity and controversial mechanisms of action hamper their use as effective antitumor agents in the clinic.…”

“…However, some problems such as poor solubility, toxicity and controversial mechanisms of action hamper their use as effective antitumor agents in the clinic. In order to accelerate the use of arteether in the clinic, researchers have recently developed novel therapeutic approaches including developing novel derivatives, manufacturing novel nano-formulations and combining arteether with other drugs for cancer therapy [ 54 , 55 ].…”

Malaria and tuberculosis as diseases of neglected populations: state of the art in chemotherapy and advances in the search for new drugs

“…Herein, both treatments were found not to interfere significantly with each other's pharmacokinetics in the reported group of healthy volunteers, supporting the use of these two treatments as a new combination therapy for malaria. (29) Naphthoquine (Fig. 4) is a 4-aminoquinoline developed in China and synthesised in 1986.…”

“…Its combination with clindamycin has already been trialed and has presented initial success for malaria treatment, however, a more recent trial reported unfavorable results for this combination. (9,29) Fosmidomycin was also trialed in combination with primaquine in Gabon and showed promising results. The study was designed as a proof-of-concept and evaluated the efficacy, tolerability and safety of the combination therapy and thus did not include a control population.…”

Antimalaria Medicine and Its Mechanism : A Review

“…The half-life of Sulfadoxine and Pyrimethamine is~169 hours and~111 hours α/β-Arteether is a CYP3A4/5 substrate, whereas sulfadoxine-pyrimethamine has no interaction with CYP3A4/5 22 .…”